Bridge-building between communities: Imagining the future of biomedical autism research

Síofra Heraty; Alexandra Lautarescu; David Belton; Alison Boyle; Pietro Cirrincione; Mary Doherty; Sarah Douglas; Jan Roderik Derk Plas; Katrien Van Den Bosch; Pierre Violland; Jerneja Tercon; Amber Ruigrok; Declan G.M. Murphy; Thomas Bourgeron; Christopher Chatham; Eva Loth; Bethany Oakley; Grainne M. McAlonan; Tony Charman; Nicolaas Puts; Louise Gallagher; Emily J.H. Jones

doi:10.1016/j.cell.2023.08.004

Bridge-building between communities: Imagining the future of biomedical autism research

Síofra Heraty, Alexandra Lautarescu, David Belton, Alison Boyle, Pietro Cirrincione, Mary Doherty, Sarah Douglas, Jan Roderik Derk Plas, Katrien Van Den Bosch, Pierre Violland, Jerneja Tercon, Amber Ruigrok, Declan G.M. Murphy, Thomas Bourgeron, Christopher Chatham, Eva Loth, Bethany Oakley, Grainne M. McAlonan, Tony Charman, Nicolaas PutsLouise Gallagher, Emily J.H. Jones

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

A paradigm shift in research culture is required to ease perceived tensions between autistic people and the biomedical research community. As a group of autistic and non-autistic scientists and stakeholders, we contend that through participatory research, we can reject a deficit-based conceptualization of autism while building a shared vision for a neurodiversity-affirmative biomedical research paradigm.

Original language	English
Pages (from-to)	3747-3752
Number of pages	6
Journal	Cell
Volume	186
Issue number	18
DOIs	https://doi.org/10.1016/j.cell.2023.08.004
Publication status	Published - 31 Aug 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.cell.2023.08.004

Cite this

Heraty, S., Lautarescu, A., Belton, D., Boyle, A., Cirrincione, P., Doherty, M., Douglas, S., Plas, J. R. D., Van Den Bosch, K., Violland, P., Tercon, J., Ruigrok, A., Murphy, D. G. M., Bourgeron, T., Chatham, C., Loth, E., Oakley, B., McAlonan, G. M., Charman, T., ... Jones, E. J. H. (2023). Bridge-building between communities: Imagining the future of biomedical autism research. Cell, 186(18), 3747-3752. https://doi.org/10.1016/j.cell.2023.08.004

@article{2cd252e2a90246c6a42c3e66df6b6f94,

title = "Bridge-building between communities: Imagining the future of biomedical autism research",

abstract = "A paradigm shift in research culture is required to ease perceived tensions between autistic people and the biomedical research community. As a group of autistic and non-autistic scientists and stakeholders, we contend that through participatory research, we can reject a deficit-based conceptualization of autism while building a shared vision for a neurodiversity-affirmative biomedical research paradigm.",

author = "S{\'i}ofra Heraty and Alexandra Lautarescu and David Belton and Alison Boyle and Pietro Cirrincione and Mary Doherty and Sarah Douglas and Plas, {Jan Roderik Derk} and {Van Den Bosch}, Katrien and Pierre Violland and Jerneja Tercon and Amber Ruigrok and Murphy, {Declan G.M.} and Thomas Bourgeron and Christopher Chatham and Eva Loth and Bethany Oakley and McAlonan, {Grainne M.} and Tony Charman and Nicolaas Puts and Louise Gallagher and Jones, {Emily J.H.}",

note = "Funding Information: This project has received funding from the Innovative Medicines Initiative Joint Undertaking under grant agreement no. 115300 , resources of which are composed of financial contribution from the European Union{\textquoteright}s Seventh Framework Programme ( FP7/2007–2013 ), EFPIA companies{\textquoteright} in-kind contribution, and the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 777394 . This Joint Undertaking receives support from the European Union{\textquoteright}s Horizon 2020 research and innovation program, EFPIA , AUTISM SPEAKS , Autistica , and SFARI and awards from the Medical Research Council ( MR/K021389/1 ; MR/T003057/1 ). The IHI-JU2 had no role in the writing of this manuscript, or in the decision to publish it. Any views expressed are those of the author(s) and not necessarily those of the IHI-JU2. D.G.M.M. and G.M. also acknowledge support from the National Institute for Health Research ( NIHR ) Mental Health Biomedical Research Center (BRC) at South London, the Maudsley NHS Foundation Trust , and King{\textquoteright}s College London . The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care. Funding Information: This project has received funding from the Innovative Medicines Initiative Joint Undertaking under grant agreement no. 115300, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007–2013), EFPIA companies{\textquoteright} in-kind contribution, and the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 777394. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation program, EFPIA, AUTISM SPEAKS, Autistica, and SFARI and awards from the Medical Research Council (MR/K021389/1; MR/T003057/1). The IHI-JU2 had no role in the writing of this manuscript, or in the decision to publish it. Any views expressed are those of the author(s) and not necessarily those of the IHI-JU2. D.G.M.M. and G.M. also acknowledge support from the National Institute for Health Research (NIHR) Mental Health Biomedical Research Center (BRC) at South London, the Maudsley NHS Foundation Trust, and King's College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care. Conceptualization, S.H. A.L. D.B. A.B. P.C. M.D. S.D. J.R.D.P. K.V.D.B. P.V. A.R. and E.J.; project administration, S.H. and E.J.; writing – original draft, S.H. A.L. D.B. A.B. P.C. M.D. S.D. J.R.D.P. K.V.D.B. P.V. A.R. T.B. C.C. E.L. B.O. G.M.A. T.C. N.P. and L.G.; writing – review and editing, S.H. A.L. D.B. A.B. P.C. M.D. S.D. J.R.D.P. K.V.D.B. P.V. A.R. D.M. T.B. C.C. E.L. B.O. G.M.A. T.C. N.P. L.G. and E.J.; funding acquisition, D.M. C.C. E.L. G.M. T.C. L.G. E.J. and A.R.; supervision, E.J. In the past three years, T.C. has served as a paid consultant to F. Hoffmann-La Roche Ltd. and Servier and has received royalties from Sage Publications and Guilford Publications. C.C. is a full-time employee of Genentech and owns stocks or RSUs in Roche Holdings, Ltd. One or more of the authors of this paper self-identifies as an underrepresented ethnic minority in their field of research or within their geographical location. One or more of the authors of this paper self-identifies as a gender minority in their field of research. One or more of the authors of this paper self-identifies as a member of the LGBTQIA+ community. One or more of the authors of this paper self-identifies as living with a disability. One or more of the authors of this paper received support from a program designed to increase minority representation in their field of research. Publisher Copyright: {\textcopyright} 2023 Elsevier Inc.",

year = "2023",

month = aug,

day = "31",

doi = "10.1016/j.cell.2023.08.004",

language = "English",

volume = "186",

pages = "3747--3752",

journal = "Cell",

issn = "1097-4172",

publisher = "Elsevier",

number = "18",

}

Heraty, S, Lautarescu, A, Belton, D, Boyle, A, Cirrincione, P, Doherty, M, Douglas, S, Plas, JRD, Van Den Bosch, K, Violland, P, Tercon, J, Ruigrok, A, Murphy, DGM, Bourgeron, T, Chatham, C, Loth, E , Oakley, B , McAlonan, GM , Charman, T , Puts, N, Gallagher, L & Jones, EJH 2023, 'Bridge-building between communities: Imagining the future of biomedical autism research', Cell, vol. 186, no. 18, pp. 3747-3752. https://doi.org/10.1016/j.cell.2023.08.004

TY - JOUR

T1 - Bridge-building between communities

T2 - Imagining the future of biomedical autism research

AU - Heraty, Síofra

AU - Lautarescu, Alexandra

AU - Belton, David

AU - Boyle, Alison

AU - Cirrincione, Pietro

AU - Doherty, Mary

AU - Douglas, Sarah

AU - Plas, Jan Roderik Derk

AU - Van Den Bosch, Katrien

AU - Violland, Pierre

AU - Tercon, Jerneja

AU - Ruigrok, Amber

AU - Murphy, Declan G.M.

AU - Bourgeron, Thomas

AU - Chatham, Christopher

AU - Loth, Eva

AU - Oakley, Bethany

AU - McAlonan, Grainne M.

AU - Charman, Tony

AU - Puts, Nicolaas

AU - Gallagher, Louise

AU - Jones, Emily J.H.

N1 - Funding Information: This project has received funding from the Innovative Medicines Initiative Joint Undertaking under grant agreement no. 115300 , resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme ( FP7/2007–2013 ), EFPIA companies’ in-kind contribution, and the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 777394 . This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program, EFPIA , AUTISM SPEAKS , Autistica , and SFARI and awards from the Medical Research Council ( MR/K021389/1 ; MR/T003057/1 ). The IHI-JU2 had no role in the writing of this manuscript, or in the decision to publish it. Any views expressed are those of the author(s) and not necessarily those of the IHI-JU2. D.G.M.M. and G.M. also acknowledge support from the National Institute for Health Research ( NIHR ) Mental Health Biomedical Research Center (BRC) at South London, the Maudsley NHS Foundation Trust , and King’s College London . The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care. Funding Information: This project has received funding from the Innovative Medicines Initiative Joint Undertaking under grant agreement no. 115300, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007–2013), EFPIA companies’ in-kind contribution, and the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 777394. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation program, EFPIA, AUTISM SPEAKS, Autistica, and SFARI and awards from the Medical Research Council (MR/K021389/1; MR/T003057/1). The IHI-JU2 had no role in the writing of this manuscript, or in the decision to publish it. Any views expressed are those of the author(s) and not necessarily those of the IHI-JU2. D.G.M.M. and G.M. also acknowledge support from the National Institute for Health Research (NIHR) Mental Health Biomedical Research Center (BRC) at South London, the Maudsley NHS Foundation Trust, and King's College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care. Conceptualization, S.H. A.L. D.B. A.B. P.C. M.D. S.D. J.R.D.P. K.V.D.B. P.V. A.R. and E.J.; project administration, S.H. and E.J.; writing – original draft, S.H. A.L. D.B. A.B. P.C. M.D. S.D. J.R.D.P. K.V.D.B. P.V. A.R. T.B. C.C. E.L. B.O. G.M.A. T.C. N.P. and L.G.; writing – review and editing, S.H. A.L. D.B. A.B. P.C. M.D. S.D. J.R.D.P. K.V.D.B. P.V. A.R. D.M. T.B. C.C. E.L. B.O. G.M.A. T.C. N.P. L.G. and E.J.; funding acquisition, D.M. C.C. E.L. G.M. T.C. L.G. E.J. and A.R.; supervision, E.J. In the past three years, T.C. has served as a paid consultant to F. Hoffmann-La Roche Ltd. and Servier and has received royalties from Sage Publications and Guilford Publications. C.C. is a full-time employee of Genentech and owns stocks or RSUs in Roche Holdings, Ltd. One or more of the authors of this paper self-identifies as an underrepresented ethnic minority in their field of research or within their geographical location. One or more of the authors of this paper self-identifies as a gender minority in their field of research. One or more of the authors of this paper self-identifies as a member of the LGBTQIA+ community. One or more of the authors of this paper self-identifies as living with a disability. One or more of the authors of this paper received support from a program designed to increase minority representation in their field of research. Publisher Copyright: © 2023 Elsevier Inc.

PY - 2023/8/31

Y1 - 2023/8/31

N2 - A paradigm shift in research culture is required to ease perceived tensions between autistic people and the biomedical research community. As a group of autistic and non-autistic scientists and stakeholders, we contend that through participatory research, we can reject a deficit-based conceptualization of autism while building a shared vision for a neurodiversity-affirmative biomedical research paradigm.

AB - A paradigm shift in research culture is required to ease perceived tensions between autistic people and the biomedical research community. As a group of autistic and non-autistic scientists and stakeholders, we contend that through participatory research, we can reject a deficit-based conceptualization of autism while building a shared vision for a neurodiversity-affirmative biomedical research paradigm.

UR - http://www.scopus.com/inward/record.url?scp=85169521386&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2023.08.004

DO - 10.1016/j.cell.2023.08.004

M3 - Article

C2 - 37657415

AN - SCOPUS:85169521386

SN - 1097-4172

VL - 186

SP - 3747

EP - 3752

JO - Cell

JF - Cell

IS - 18

ER -

Bridge-building between communities: Imagining the future of biomedical autism research

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this